Acenocoumarol as an alternative anticoagulant in a patient with warfarin‐related nephropathy

Behera, Sapan Kumar; Xavier, Alphienes Stanley; Selvarajan, Sandhiya; Munuswamy, Hemachandren; Haridasan, Satish; Srinivas, Bheemanathi Hanuman

doi:10.1111/bcp.13541

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the past decades, vitamin K antagonists have been shown to have anticoagulant properties. The most important vitamin K antagonists that are currently in use are dicoumarol warfarin, phenprocoumon, acenocoumarol and rivaroxaban [ 239 – 242 ]. However, risk of a recurrent event among patients with venous thromboembolism has shown to be decreased with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates [ 243 ].…”

Section: Platelets Hyperactivity In T2dmmentioning

confidence: 99%

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Kaur

Singh

2018

Cardiovasc Diabetol

499

363

View full text Add to dashboard Cite

The incidence and prevalence of diabetes mellitus is rapidly increasing worldwide at an alarming rate. Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, accounting for approximately 90–95% of the total diabetes cases worldwide. Besides affecting the ability of body to use glucose, it is associated with micro-vascular and macro-vascular complications. Augmented atherosclerosis is documented to be the key factor leading to vascular complications in T2DM patients. The metabolic milieu of T2DM, including insulin resistance, hyperglycemia and release of excess free fatty acids, along with other metabolic abnormalities affects vascular wall by a series of events including endothelial dysfunction, platelet hyperactivity, oxidative stress and low-grade inflammation. Activation of these events further enhances vasoconstriction and promotes thrombus formation, ultimately resulting in the development of atherosclerosis. All these evidences are supported by the clinical trials reporting the importance of endothelial dysfunction and platelet hyperactivity in the pathogenesis of atherosclerotic vascular complications. In this review, an attempt has been made to comprehensively compile updated information available in context of endothelial and platelet dysfunction in T2DM.

show abstract

Section: Platelets Hyperactivity In T2dmmentioning

confidence: 99%

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Kaur

Singh

2018

Cardiovasc Diabetol

499

363

View full text Add to dashboard Cite

show abstract

“…Over previous decades, it has been demonstrated that vitamin K antagonists possess anticoagulant characteristics. Dicoumarol, warfarin, phenprocoumon, acenocoumarol, and rivaroxaban are among the most significant vitamin K antagonists presently employed ( 188 ). Compared to aspirin, rivaroxaban reduced the risk of recurrence in patients with venous thromboembolism without significantly increasing the risk of bleeding ( 189 ).…”

Section: Role Of Mets On Platelet Hyperactivitymentioning

confidence: 99%

Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies

Das

Banerjee

et al. 2023

Front. Nutr.

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a multifaceted condition that increases the possibility of developing atherosclerotic cardiovascular disease. MetS includes obesity, hypertension, dyslipidemia, hyperglycemia, endothelial dysfunction, and platelet hyperactivity. There is a concerning rise in the occurrence and frequency of MetS globally. The rising incidence and severity of MetS need a proactive, multipronged strategy for identifying and treating those affected. For many MetS patients, achieving recommended goals for healthy fat intake, blood pressure control, and blood glucose management may require a combination of medicine therapy, lifestyles, nutraceuticals, and others. However, it is essential to note that lifestyle modification should be the first-line therapy for MetS. In addition, MetS requires pharmacological, nutraceutical, or other interventions. This review aimed to bring together the etiology, molecular mechanisms, and dietary strategies to combat hypertension, endothelial dysfunction, and platelet dysfunction in individuals with MetS.

show abstract

“…Pathological states before the development of ecchymosis include disorders of coagulation pathways and platelets in addition to causing hematoma formation and disorders of dermal connective tissues. 1,2…”

Section: Anticoagulant-induced Ecchymosismentioning

confidence: 99%

Anticoagulants Induced Ecchymosis

Nagasubbu,

Mohan,

Selvam

2023

NJEM

View full text Add to dashboard Cite

show abstract

Acenocoumarol as an alternative anticoagulant in a patient with warfarin‐related nephropathy

Abstract: Further prospectively designed studies are needed to consider acenocoumarol as an alternative therapy in warfarin-related nephropathy.

Cited by 6 publications

References 8 publications

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies

Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies

Anticoagulants Induced Ecchymosis

Contact Info

Product

Resources

About